Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: GermlineBRCAmutation carriers and wild-typeBRCApancreatic ductal adenocarcinoma-Reference-Cited by-同舟云学术

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: GermlineBRCAmutation carriers and wild-typeBRCApancreatic ductal adenocarcinoma

Published:2018-01-16 Issue:7 Volume:124 Page:1374-1382
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

O'Reilly Eileen M.¹²^ORCID,Lee Jonathan W.¹,Lowery Maeve A.¹,Capanu Marinela¹,Stadler Zsofia K.¹²,Moore Malcolm J.³,Dhani Neesha³,Kindler Hedy L.⁴,Estrella Hayley¹,Maynard Hannah¹,Golan Talia⁵⁶,Segal Amiel⁷,Salo-Mullen Erin E.¹,Yu Kenneth H.¹²,Epstein Andrew S.¹²,Segal Michal¹,Brenner Robin¹,Do Richard K.¹²,Chen Alice P.⁸,Tang Laura H.¹²,Kelsen David P.¹²

Affiliation:

1. Memorial Sloan Kettering Cancer Center; New York New York

2. Weill Cornell Medicine; New York New York

3. Princess Margaret Cancer Centre; University Health Network; Toronto Ontario Canada

4. University of Chicago Medical Center; Chicago Illinois

5. Sheba Medical Center; Tel Hashomer Israel

6. Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv Israel

7. Share Zedek Medical Center; Jerusalem Israel

8. National Cancer Institute; Bethesda Maryland

Funder

Lustgarten Foundation

David M. Rubenstein Center for Pancreatic Cancer Research